Welcome to our dedicated page for Bon Natural Life SEC filings (Ticker: BON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bon Natural Life Limited’s SEC disclosures are more than numbers—they chart the evolution of a high-growth botanicals innovator now branching into “green� spirits. Whether you’re tracking how patent filings translate into revenue or how the Jiangwang distribution deal reshapes margins, the details live inside BON’s 10-K, 10-Q, and 8-K reports.
Our platform delivers AI-powered summaries that make sense of every section. Want to see Bon Natural Life insider trading Form 4 transactions the moment they post? AGÕæÈ˹ٷ½-time alerts flag each officer’s trade. Need the latest Bon Natural Life quarterly earnings report 10-Q filing? We break down ingredient segment performance, raw material costs, and overseas sales growth within minutes. From Bon Natural Life executive stock transactions Form 4 to a Bon Natural Life proxy statement executive compensation table, Stock Titan translates dense language into clear insights.
Use cases include:
- Compare R&D spend on new plant extracts across successive 10-Qs.
- Monitor capacity expansion updates via Bon Natural Life 8-K material events explained.
- Evaluate strategic risks in the Bon Natural Life annual report 10-K simplified.
Because filings don’t wait, neither do we. AGÕæÈ˹ٷ½-time EDGAR feeds stream every documentâ€�10-K, 10-Q, 8-K, S-1, and especially Bon Natural Life Form 4 insider transactions real-time. Our expert analysis pairs context from the functional food and personal-care markets with easy-to-read charts, ensuring you understand each disclosure without parsing hundreds of pages. In short, it’s Bon Natural Life SEC filings explained simply—so you can focus on decisions, not document hunts.
On 4 July 2025, Bon Natural Life’s subsidiary Xi’an App-Chem Bio (Tech) Co., Ltd. signed a 36-month Sales Cooperation Agreement with Beijing Huahai Keyuan Technology Co., Ltd. granting the distributor a non-exclusive right to market the company’s natural weight-loss products in China and Southeast Asia.
- Guaranteed sales: Huahai Keyuan commits to minimum aggregate purchases of US$22 million during the contract term; App-Chem must receive full payment before shipment.
- Responsibilities: App-Chem handles R&D, manufacturing and quality control; it bears testing and return costs if product quality fails agreed standards.
- Logistics: Products shipped to sites designated by Huahai Keyuan.
- Termination & penalties: Agreement may be ended by mutual consent or after a 30-day cure period for breaches. Unjustified termination triggers liquidated damages of 15 % of total contract value; partial non-performance penalty equals 10 % of the unperformed portion.
- Disputes will be adjudicated in courts where App-Chem is located.
No financial statements were included; the filing primarily discloses the contract and a related press release (Ex. 99.1).
Bon Natural Life Limited (Nasdaq: BON) filed a Form 6-K announcing that the Nasdaq Hearings Panel has granted continued listing status after the company rectified its minimum bid price deficiency cited in May 2025.
Highlights
- Compliance regained: On 2 July 2025 the Panel confirmed BON now meets Listing Rule 5550(a)(2) (US$1.00 minimum bid price).
- Ongoing oversight: Nasdaq imposed a one-year Discretionary Panel Monitor to track future compliance and public-interest matters.
- Dilution spotlight: The March 2025 financing issued 101,250,968 Class A shares; warrants could add 8,333,332 more (total potential 116,666,648), triggering Nasdaq concerns.
- Mitigation steps: Management is negotiating amendments with March investors, has launched a share-repurchase program, and pledges to avoid “overly complex or inherently dilutive� instruments in future.
- Governance & controls: BON will enhance board independence, introduce mandatory pre-issuance checklists, assign dedicated Nasdaq-compliance staff, provide regular training, and retain external legal/compliance advisers.
No financial or earnings data were provided. The filing primarily reassures investors that the U.S. listing is intact while acknowledging dilution risks and outlining governance reforms to rebuild market confidence.
Bon Natural Life Limited (BON) � Form 6-K, July 2025
The filing reports that subsidiary Xi’an App-Chem Bio (Tech) Co., Ltd. signed a 24-month Sales Cooperation Agreement with Beijing Huahai Keyuan Technology Co., Ltd. on 10 June 2025. Huahai Keyuan receives a non-exclusive right to market, distribute and sell App-Chem’s natural prebiotic series products throughout China.
Key commercial terms
- Guaranteed sales: Huahai Keyuan commits to purchase at least US$16 million of products over the two-year term.
- Revenue recognition & cash risk: App-Chem must receive full payment in advance before dispatch, materially reducing counter-party credit exposure.
- Operational obligations: App-Chem handles R&D, production, packaging and quality control to ensure compliance with Chinese national standards. If product quality fails, App-Chem bears all associated testing and return costs.
- Termination & penalties: � Either party may terminate by mutual consent.
� Cure period for breach: 30 working days.
� Wrongful termination triggers liquidated damages equal to 15 % of the total contract value.
� Partial non-performance penalty: 10 % of the unperformed portion. - Jurisdiction: Disputes to be litigated in a court located where the Company is registered.
The agreement provides BON with a sizeable minimum revenue pipeline, enhances cash flow security via pre-payment, and expands distribution reach within China. However, the deal is non-exclusive, exposes the company to product-quality liabilities, and the guaranteed figure’s materiality to overall revenues is not disclosed.